CHARLESTON, S.C., May 12, 2010 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revmed" or the "Company") (OTCBB:RMCP), has signed an agreement of understanding for the setting up of a manufacturing facility in Brazil to produce the RevVac safety syringe for domestic and global markets and to facilitate distribution throughout South America.
Santa Monica Pharmaceutica Ltda has been formed and funded for the specific purpose of manufacturing and distribution of the RevMed proprietary RevVac safety syringe.
"In Santa Monica Pharmaceutica Ltda, we could not have found a more committed strategic partner who shares our vision of reducing unnecessary accidental needle stick injuries and the promoting of healthcare safety. They also share our belief that our proprietary auto retractable vacuum safety syringe technology is the future and has many advantages over older auto retractable technologies currently available in the market place. Also, the commitment by the Brazilian state government legislating mandatory safety syringe, played a major part in our final decision to execute this strategic relationship in Brazil. I believe upon completion of final documents, the long anticipated launch of the mass production of our RevVac safety syringe, after the success of the pilot run announced in December, has finally arrived. We could not be more excited to be working in this strategic partnership with Santa Monica Pharmaceutica Ltda," states Ron Wheet CEO, RevMed.
Nick Ogle Commercial Director of Libra international states, "Since December when we were engaged by RevMed we have completed a stringent vetting process adhering to strict criteria in order to find the ideal strategic partner. The criteria included: commitment to a rapid production schedule, manufacturing expertise, distribution outlets and similar values and goals. The combination of RevMed's superior technology and attention to detail and Santa Monica Pharmaceutica Ltda's manufacturing capability and enthusiasm makes this the perfect strategic partnership."
Clive Davies Managing Director of Libra International, who now resides in Brazil states, " Not only is this a win, win situation for RevMed and Santa Monica but also for Brazil which has secured initial global production and all the prestige that comes with having beaten off stiff international competition for such a world class product."
About Revolutions Medical Corporation
(http://www.revolutionsmedical.com)
RevMed's products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.
Investor Resource Center
Fact Sheet: http://content.stockpr.com/rmcp/files/RMCP+-+Fact+Sheet+02-26-10.pdf
CEO Ron Wheet Audio Interview: http://ir.stockpr.com/revolutionsmedical/media-center/view/33/
RevVac Demo Video: http://revolutionsmedical.com/play_video.htm
To be added to the Revolutions Medical investor email list, please email Skey@revolutionsmedical.com with RMCP in the subject line.
Become a RevMed fan and follow the Company on Facebook - visit http://www.facebook.com/RevMed
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.